The company intends to use the funds for: Completion of clinical PoC of its AAVB-039 CELESTE study for Stargardt disease caused by a mutation in the ABCA4 gene and the completion of the > 100 patient STELLA natural history study. Completion of clinical PoC of its AAVB-081 LUCE phase 1/2 clinical trial for retinitis pigmentosa (RP) secondary to Usher 1B due to a mutation in the MYO7A gene.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Via Vincenzo Gioberti, 8
Milano, 20123
iT

Phone

+39 02 83991300

Website

www.aavantgardebio.com

Email Address

[email protected]

Overview

AAVantgarde Bio is a clinical stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. This platform is being clinically validated in two Inherited Retinal Diseases; Usher1B and Stargardt disease, and the platform is expected to address the gene therapy cargo capacity limitations of AAV vectors and therefore the future pipeline could extend into many disease areas.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Natalia Misciattelli

Chief Medical Officer

Naveed Shams

Founder

Alberto Auricchio

Browse more venture capital transactions:

Prev: 11/6/2025: Evotrex venture capital transaction
Next: 11/6/2025: myLaurel venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary